Journal
INTERNATIONAL IMMUNOLOGY
Volume 27, Issue 1, Pages 55-62Publisher
OXFORD UNIV PRESS
DOI: 10.1093/intimm/dxu102
Keywords
anti-cytokine therapy; atherosclerosis; fibrosis; fractures; rheumatoid arthritis
Categories
Funding
- Arthritis Research Campaign, Centocor Inc.
- Medical Research Council
- Wellcome Trust
- Nuffield Foundation
Ask authors/readers for more resources
While for a century therapeutics has been dominated by small molecules, i.e. organic chemicals of similar to 400 Da absorbable via the gut, this is no longer the case. There are now a plethora of important medicines which are proteins and injectable, which have dramatically improved the therapy of many inflammatory diseases and of cancer. Most of these are monoclonal antibodies, some are receptor ig Fc fusion proteins, others are cytokines or enzymes. The key to this new aspect of therapeutics has been the filling of unmet needs, and the consequent commercial success, which promoted further research and development. The first 'biologic' for a common disease, rheumatoid arthritis (RA), was a monoclonal antibody, infliximab, to human tumour necrosis factor (TNF). This was based on our work, which is described in this review, summarizing how TNF was defined as a good target in RA, how it was developed is described here, as well as future indications for anti-TNF and related agents. Biologics are now the fastest growing sector of therapeutics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available